New oral seizure drug under watch in japan
NCT ID NCT05313308
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 30 times
Summary
This study monitors the safety and effectiveness of a midazolam oral solution for people with a severe, prolonged seizure called status epilepticus. About 50 participants in Japan will receive the drug as part of their normal care, and doctors will track side effects and whether seizures stop within 10 minutes for 6 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EPILEPSY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Clinigen selected site
RECRUITINGTokyo, Japan
Conditions
Explore the condition pages connected to this study.